よむ、つかう、まなぶ。
参考資料３ WHO Statement on the antigen composition of COVID-19 vaccines (6 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/newpage_00104.html |
| 出典情報 | 厚生科学審議会 予防接種・ワクチン分科会 研究開発及び生産・流通部会 季節性インフルエンザワクチンの製造株について検討する小委員会（第2回 5／29）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
updated comDposition. WHO stresses the importance of access to and eduity in the use
of al available COVID-19 vaccines.
Further data reduirements and considerationSs
Given the limitations of the evidence upon which the recommendations above are
derived and the anticipated continued evolution of the virus, the TAG-CO-VAC strongly
encouradges deneration of data on immune responses and clinical endpoints (i.e. VE)
onthe performance of all currently approved COVID-19 vaccines against emerging
SARS-CoV-2 variants, and candidate vaccines with an updated antigen over time.
As previously stated, the TAG-CO-VAC continues to encourade the further
development of vaccines that may improve protection against infection and reduce
transmission of SARS-CoV-2.
More 70O 60/7O/S:
On 7 May 2024, the following text in this statement:
"One approach recommended by TAG-CO-VAC is the use of a monovalent」N.1 lineage
(GenBank: OY817255.1, GISAID: EPI_ ISL_ 18538117, WHO Biohub: 2024-WHO-LS-001)
antiden In VaccineS.“
was replaced with:
"One approach recommended by TAG-CO-VAC is the use of a monovalent 」N.1 lineage
(GISAID: EPI_ISL_19096142, WHO Biohub: 2024-WHO-LS-001) antigen in vaccines."
The GenBank and GISAID accession numbers of the Virus seduence diven as an
exarmDple」N.1 lineage in the version of the statement published on 26 April 2024 lacked
an insertion in the spike N-terminal domain (i.e. ins16MPLF) that is usually present in
JN.1 and its descendent lineages. This is the result of a known technical issue
associated with the bioinformatic analysis (Rothstein A et al. bioRxiv (Dreprint server).
2023: doi: 10.1101/2023.09.08.556912), rather than the lack of the above mentioned
Insertion in the isolate.
On 14 May 2024, the following text in the statement:
of al available COVID-19 vaccines.
Further data reduirements and considerationSs
Given the limitations of the evidence upon which the recommendations above are
derived and the anticipated continued evolution of the virus, the TAG-CO-VAC strongly
encouradges deneration of data on immune responses and clinical endpoints (i.e. VE)
onthe performance of all currently approved COVID-19 vaccines against emerging
SARS-CoV-2 variants, and candidate vaccines with an updated antigen over time.
As previously stated, the TAG-CO-VAC continues to encourade the further
development of vaccines that may improve protection against infection and reduce
transmission of SARS-CoV-2.
More 70O 60/7O/S:
On 7 May 2024, the following text in this statement:
"One approach recommended by TAG-CO-VAC is the use of a monovalent」N.1 lineage
(GenBank: OY817255.1, GISAID: EPI_ ISL_ 18538117, WHO Biohub: 2024-WHO-LS-001)
antiden In VaccineS.“
was replaced with:
"One approach recommended by TAG-CO-VAC is the use of a monovalent 」N.1 lineage
(GISAID: EPI_ISL_19096142, WHO Biohub: 2024-WHO-LS-001) antigen in vaccines."
The GenBank and GISAID accession numbers of the Virus seduence diven as an
exarmDple」N.1 lineage in the version of the statement published on 26 April 2024 lacked
an insertion in the spike N-terminal domain (i.e. ins16MPLF) that is usually present in
JN.1 and its descendent lineages. This is the result of a known technical issue
associated with the bioinformatic analysis (Rothstein A et al. bioRxiv (Dreprint server).
2023: doi: 10.1101/2023.09.08.556912), rather than the lack of the above mentioned
Insertion in the isolate.
On 14 May 2024, the following text in the statement: